Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.

Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Lévy C, Laborde L, Uwer L, D'hondt V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T.

Eur J Cancer. 2019 Sep;118:131-141. doi: 10.1016/j.ejca.2019.06.014. Epub 2019 Jul 19.

PMID:
31330488
2.

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin MP, Lesoin A, Rezai K, Lokiec FM, Lhomme C, Bosq J, Bexon AS, Gilles EM, Proniuk S, Dieras V, Jackson DM, Zukiwski A, Italiano A.

PLoS One. 2018 Oct 10;13(10):e0204973. doi: 10.1371/journal.pone.0204973. eCollection 2018.

3.

Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.

Laroche F, Perrot S, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Chauvenet L, Bouhassira D, Coste J.

PLoS One. 2017 Nov 8;12(11):e0187165. doi: 10.1371/journal.pone.0187165. eCollection 2017.

4.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
5.

[Systemic neoadjuvant therapy of luminal breast cancer in 2016].

Cottu PH.

Bull Cancer. 2017 Jan;104(1):69-78. doi: 10.1016/j.bulcan.2016.09.021. Epub 2016 Nov 3. Review. French.

PMID:
27817858
6.

Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.

Hurtaud A, Donnadieu A, Escalup L, Cottu PH, Baffert S.

Breast. 2016 Dec;30:73-79. doi: 10.1016/j.breast.2016.08.015. Epub 2016 Sep 14.

PMID:
27639032
7.

Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys.

Cutuli B, Dalenc F, Cottu PH, Gligorov J, Guastalla JP, Petit T, Amrate A.

Cancer Radiother. 2015 Aug;19(5):295-302. doi: 10.1016/j.canrad.2015.02.015. Epub 2015 Jul 15.

PMID:
26188735
8.

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

Genome Biol. 2015 May 22;16:107. doi: 10.1186/s13059-015-0657-6.

9.

Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas.

Cabel L, Péron J, Cottu PH, Rodrigues MJ.

J Clin Oncol. 2015 Jan 20;33(3):291. doi: 10.1200/JCO.2014.58.6941. Epub 2014 Dec 15. No abstract available.

PMID:
25512462
10.

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M.

Br J Cancer. 2014 Mar 18;110(6):1413-9. doi: 10.1038/bjc.2014.81. Epub 2014 Feb 25.

11.

Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S.

J Pain. 2014 Mar;15(3):293-303. doi: 10.1016/j.jpain.2013.11.004. Epub 2013 Dec 21.

PMID:
24365325
12.

Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa.

Comte A, Jdid W, Guilhaume MN, Kriegel I, Piperno-Neumann S, Dieras V, Dorval T, Pierga JY, Cottu PH, Mignot L, Bidard FC.

J Neurooncol. 2013 Dec;115(3):445-52. doi: 10.1007/s11060-013-1244-x. Epub 2013 Sep 17.

PMID:
24043602
13.

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.

Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH.

Ann Oncol. 2013 Apr;24(4):916-24. doi: 10.1093/annonc/mds536. Epub 2012 Oct 26.

PMID:
23104720
14.

Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy.

Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I.

J Wound Care. 2011 Sep;20(9):403-4, 406, 408 passim.

PMID:
22068139
15.

Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy.

Kriegel I, Cottu PH, Fourchotte V, Sanchez S, Fromantin I, Kirov K, Guillaume A, Pelloquin A, Esteve M, Salmon RJ.

Anticancer Drugs. 2011 Nov;22(10):1020-3. doi: 10.1097/CAD.0b013e328349c7bb.

PMID:
21970853
16.

Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.

Rodrigues MJ, Albiges-Sauvin L, Wassermann J, Cottu PH.

Ann Oncol. 2011 Nov;22(11):2530. doi: 10.1093/annonc/mdr308. Epub 2011 Jun 23. No abstract available.

PMID:
21700734
17.

[Survival of breast cancers patients with meningeal carcinoma].

Petithuguenin Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V.

Bull Cancer. 2011 Apr;98(4):391-8. doi: 10.1684/bdc.2011.1340. French.

18.

[Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience].

Gachet J, Giroux J, Girre V, Brain É, Kirova Y, Mignot L, Mazeron JJ, Dutertre G, Pouit B, Mosseri V, Falcou MC, Cottu PH.

Bull Cancer. 2011 Apr;98(4):357-69. doi: 10.1684/bdc.2011.1339. French.

19.

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

Staudacher L, Cottu PH, Diéras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY.

Ann Oncol. 2011 Apr;22(4):848-56. doi: 10.1093/annonc/mdq461. Epub 2010 Oct 5.

PMID:
20924076
20.

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.

Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretière JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, Cottu PH.

J Clin Oncol. 2010 Oct 1;28(28):e541-2. doi: 10.1200/JCO.2010.29.7952. Epub 2010 Jul 26. No abstract available.

PMID:
20660834
21.

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Meyniel JP, Cottu PH, Decraene C, Stern MH, Couturier J, Lebigot I, Nicolas A, Weber N, Fourchotte V, Alran S, Rapinat A, Gentien D, Roman-Roman S, Mignot L, Sastre-Garau X.

BMC Cancer. 2010 May 21;10:222. doi: 10.1186/1471-2407-10-222.

22.

Survival of breast cancer patients with meningeal carcinomatosis.

Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Diéras V.

Ann Oncol. 2010 Nov;21(11):2183-7. doi: 10.1093/annonc/mdq232. Epub 2010 Apr 29.

PMID:
20430906
23.

[Locally advanced (neglected) breast cancer: the reality? Relevance of two cases and reflection how to optimise the multidisciplinary approach].

Monnier L, Even C, Cottu PH, Kirova YM.

Cancer Radiother. 2009 Jul;13(4):333-6. doi: 10.1016/j.canrad.2009.04.002. Epub 2009 Jun 12. French.

PMID:
19524471
24.

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

Chargari C, Kirova YM, Diéras V, Castro Pena P, Campana F, Cottu PH, Pierga J, Fourquet A; Institut Curie Breast Cancer Study Group.

J Neurooncol. 2009 Jul;93(3):379-84. doi: 10.1007/s11060-008-9791-2. Epub 2009 Jan 25. Erratum in: J Neurooncol. 2009 Jul;93(3):385. Pena, Pablo Castro [corrected to Castro Pena, Pablo].

PMID:
19169856
25.

Meningeal carcinomatosis in HER2-overexpressing breast cancers.

Bidard FC, Guilhaume MN, Gauthier H, Cottu PH, Diéras V, Pierga JY.

J Neurooncol. 2009 Jun;93(2):287-8. doi: 10.1007/s11060-008-9768-1. Epub 2009 Jan 13. No abstract available.

PMID:
19139826
26.

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

Cottu PH, Asselah J, Lae M, Pierga JY, Diéras V, Mignot L, Sigal-Zafrani B, Vincent-Salomon A.

Ann Oncol. 2008 Mar;19(3):595-7. doi: 10.1093/annonc/mdn021. Epub 2008 Feb 13. No abstract available.

PMID:
18272907
27.

[Intraperitoneal chemotherapy in ovarian cancer].

Delemer-Lefebvre M, Ascencio M, Cottu PH, Villet R, Vinatier D, Collinet P.

Gynecol Obstet Fertil. 2007 Sep;35(9):791-6. Epub 2007 Aug 24. French.

PMID:
17719824
28.

[Initial pretherapeutic assessment of anal epidermoid carcinoma].

de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P.

Gastroenterol Clin Biol. 2007 Feb;31(2):157-65. Review. French.

29.

Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.

Caruba T, Cottu PH, Madelaine-Chambrin I, Espié M, Misset JL, Gross-Goupil M.

Breast J. 2007 Mar-Apr;13(2):165-71.

PMID:
17319858
30.

[Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia].

Albiges L, Cottu PH, Cojean-Zelek I, Raymond F, Zerkak D, Aerts J, Ziza JM.

Rev Med Interne. 2007 Mar;28(3):176-8. Epub 2007 Jan 3. French.

PMID:
17229492
31.

[Identification and management of hereditary breast-ovarian cancers (2004 update)].

Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Noguès C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R.

Pathol Biol (Paris). 2006 May;54(4):230-50. Epub 2006 May 2. Review. French.

PMID:
16632260
32.

Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study.

Gonçalves A, Delva R, Fabbro M, Gladieff L, Lotz JP, Ferrero JM, Linassier C, Cottu PH, Viens P, Extra JM.

Bone Marrow Transplant. 2006 Apr;37(7):651-9.

PMID:
16501596
33.

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E.

Ann Oncol. 2006 Mar;17(3):429-36.

PMID:
16500913
34.

A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.

Cutuli B, Cottu PH, Guastalla JP, Mechin H, Costa A, Jourdan R.

Breast Cancer Res Treat. 2006 Jan;95(1):55-64. Epub 2005 Oct 27.

PMID:
16261401
35.

[Breast carcinoma and genomic technology: contribution of DNA microarrays].

Sévenet N, Cottu PH.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S226-31. Review. French.

36.

[Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)].

Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Noguès C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R.

Bull Cancer. 2004 Mar;91(3):219-37. Review. French.

37.

[Breast cancer in young women: problem and questions].

Espié M, Cottu PH.

Pathol Biol (Paris). 2003 Sep;51(7):391-2. French. No abstract available.

PMID:
12948756
38.

High-dose adjuvant chemotherapy for breast cancer: state of the art.

Cottu PH, Cuvier C, Espié M.

Forum (Genova). 2002;12(1):36-40. Review.

PMID:
12634909
39.

[Ductal carcinomas in situ].

de Roquancourt A, Cottu PH, Cuvier C, Nowak H, Espié M.

Presse Med. 2003 Jan 25;32(3):134-40. Review. French.

PMID:
12610386
40.

[Mass screening for breast cancer].

Cottu PH, Cuvier C, Perret F, Gorins A, Espié M.

Presse Med. 2003 Jan 25;32(3):120-4. French.

PMID:
12610384
41.

[It is possible to prescribe a hormonal replacement therapy for a woman with proliferative mastopathy with atypia].

Espié M, Cuvier C, Perret F, Cottu PH.

Gynecol Obstet Fertil. 2002 Apr;30(4):331-5. French. No abstract available.

PMID:
12043510
42.

[Adjuvant treatment for breast cancer. Results of the consensus conference of Saint-Gall (February 2001)].

Espié M, Cottu PH.

Gynecol Obstet Fertil. 2002 Jan;30(1):86-8. Review. French. No abstract available.

PMID:
11875872
43.

Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical technique.

Dal Cortivo L, Cottu PH, Lotz JP, Robert I, Extra JM, Miclea JM, Marty M, Marolleau JP.

J Hematother Stem Cell Res. 2001 Dec;10(6):855-62.

PMID:
11798511
44.

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.

Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M.

Br J Cancer. 2001 Nov 2;85(9):1240-6.

45.

[Oxaliplatin: perspectives and future developments].

Marty M, Cottu PH, Lerebours F, Bedairia N, Hocini H, Espié M.

Bull Cancer. 2001 Aug;88 Spec No:S5-8. French. No abstract available.

PMID:
11567907
46.

Gastric metastases from breast cancer: a retrospective series of 12 patients.

Zelek L, Cottu PH, Mignot L, de Roquancourt A, Fizazi K, Cojean-Zelek I, Espie M, Marty M.

Am J Clin Oncol. 2001 Aug;24(4):363-5.

PMID:
11474262
47.

[Retrospective multivariate analysis of radio-pathological correlations of nonpalpable breast lesions. Experience of the Hospital Saint-Louis].

Cottu PH, Cojean-Zelek I, Bourstyn E, de Roquancourt A, Extra JM, Perret F, Gorins A, Marty M, Espié M.

Rev Med Interne. 2000 Apr;21(4):337-43. French.

PMID:
10795326
48.

[Chemoprevention of breast cancer: what to expect after Eurocancer 1999?].

Cottu PH, Espié M.

Bull Cancer. 1999 Oct;86(10):870-3. French. No abstract available.

49.

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients.

Cottu PH, Zelek L, Extra JM, Espie M, Mignot L, Morvan F, Marty M.

Ann Oncol. 1999 Jul;10(7):795-801.

PMID:
10470426
50.

Optimizing chemotherapy for patients with advanced breast cancer.

Marty M, Espie M, Cottu PH, Cuvier C, Lerebours F.

Oncology. 1999 Jul;57 Suppl 1:21-6. Review.

PMID:
10436413

Supplemental Content

Loading ...
Support Center